Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/01/2020 06/02/2020 06/03/2020 06/04/2020 06/05/2020 Date
286.64(c) 284.27(c) 277.01(c) 272.82(c) 265.69(c) Last
1 819 617 1 600 761 1 783 009 1 603 933 2 727 141 Volume
-0.46% -0.83% -2.55% -1.51% -2.61% Change
More quotes
Financials (USD)
Sales 2020 5 719 M - -
Net income 2020 1 944 M - -
Net cash position 2020 5 358 M - -
P/E ratio 2020 37,3x
Yield 2020 -
Sales 2021 6 611 M - -
Net income 2021 2 475 M - -
Net cash position 2021 7 839 M - -
P/E ratio 2021 29,1x
Yield 2021 -
Capitalization 68 887 M 68 887 M -
EV / Sales 2020 11,1x
EV / Sales 2021 9,23x
Nbr of Employees 3 000
Free-Float 72,2%
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.9%); - royalties and income from partnership, research, and development agreements (0.1%). Net sales break down geographically as follows:... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
06/03VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Ho..
AQ
06/03VERTEX PHARMACEUTICALS : Appoints Diana McKenzie to its Board of Directors
BU
05/15VERTEX PHARMACEUTICALS : New Data for Investigational CRISPR Cas9 Gene-Editing T..
AQ
05/12VERTEX PHARMACEUTICALS : 4
PU
05/12VERTEX PHARMACEUTICALS : CRISPR Therapeutics and Vertex Pharmaceuticals Announce..
AQ
05/11CRISPR THERAPEUTICS : Vertex Up After CTX001 Gets RMAT Designation
DJ
05/04VERTEX PHARMACEUTICALS : Receives European CHMP Positive Opinion for KALYDECO fo..
AQ
05/01VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
AQ
05/01VERTEX PHARMACEUTICALS : Gets European CHMP Positive Opinion for Kalydeco Expand..
DJ
05/01VERTEX PHARMACEUTICALS : Receives European CHMP Positive Opinion for KALYDECO® (..
BU
04/29VERTEX : 1Q Earnings Snapshot
AQ
04/29VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
AQ
04/29VERTEX PHARMACEUTICALS : Reports First-Quarter 2020 Financial Results
BU
04/29VERTEX PHARMACEUTICALS : Slide show Q1 results
CO
04/29VERTEX PHARMACEUTICALS : 1st quarter results
CO
More news
News in other languages on VERTEX PHARMACEUTICALS
06/03VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Ho..
06/03VERTEX PHARMACEUTICALS : Appoints Diana McKenzie to its Board of Directors
05/15VERTEX PHARMACEUTICALS : New Data for Investigational CRISPR Cas9 Gene-Editing T..
05/12VERTEX PHARMACEUTICALS : 4
05/12VERTEX PHARMACEUTICALS : CRISPR Therapeutics and Vertex Pharmaceuticals Announce..
More news
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 284,96 $
Last Close Price 265,69 $
Spread / Highest target 20,4%
Spread / Average Target 7,25%
Spread / Lowest Target -8,16%
EPS Revisions
Managers
NameTitle
Reshma Kewalramani President, Chief Executive Officer & Director
Jeffrey M. Leiden Executive Chairman
Charles F. Wagner Chief Financial Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS21.35%68 887
GILEAD SCIENCES18.11%97 264
REGENERON PHARMACEUTICALS59.00%60 784
WUXI APPTEC CO., LTD.24.27%26 509
GENMAB A/S29.16%18 964
BEIGENE, LTD.3.47%13 307